An NCI-designated Comprehensive Cancer Center
Synold-Tim

Timothy Synold

Professor, Department of Medical Oncology & Therapeutics Research
Appointments
Director, Analytical Pharmacology Core
Contact
Email: [email protected]

Research Teams

  • Analytical Pharmacology Core
  • CNS Malignancies Disease Team
  • Medical Oncology & Therapeutics Research
  • Phase I Disease Team

Timothy Synold, Pharm.D., is a clinical and molecular pharmacologist who serves as director of the Analytical Pharmacology Laboratory. He is also the scientific leader of the City of Hope Phase I Clinical Trial team and director of Pharmacology for the NCI-supported California Cancer Consortium. Dr. Synold has over 25 years experience in chemistry and pharmacology, and he is an expert in the fields of pharmacokinetics and pharmacodynamics. His current research focus involves the role of the blood-brain-barrier in central nervous system penetration of drugs.

Locations

City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med. 2001 May;7(5):584-90. PubMed PMID:11329060.
 
Gu L, Tsark WM, Brown DA, Blanchard S, Synold TW, Kane SE. A new model for studying tissue-specific mdr1a gene expression in vivo by live imaging. Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5394-9. PubMed PMID: 19282474.
 
Synold TW, Takimoto CH, Doroshow JH, Gandara D, Mani S, Remick SC, Mulkerin DL, Hamilton A, Sharma S, Raman than RK, Lenz HJ, Graham M, Longmate J, Kaufman BM, Ivy P; National Cancer Institute Organ Dysfunction Working Group. Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res. 2007 Jun 15;13(12):3660-6. PubMed PMID: 17575231.
 
Shibata SI, Chung V, Synold TW, Longmate JA, Suttle AB, Ottesen LH, Lenz HJ, Kummar S, Harvey RD, Hamilton AL, O'Neil BH, Sarantopoulos J, LoRusso P, Rudek MA, Dowlati A, Mulkerin DL, Belani CP, Gandhi L, Lau SC, Ivy SP, Newman EM. Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res. 2013 Jul 1;19(13):3631-9. PubMed PMID: 23653147.
 
Hurria A, Blanchard MS, Synold TW, Mortimer J, Chung CT, Luu T, Katheria V, Rotter AJ, Wong C, Choi A, Feng T, Ramani R, Doan CM, Brown J, Somlo G. Age-related changes in nanoparticle albumin-bound paclitaxel pharmacokinetics and pharmacodynamics: influence of chronological versus functional age. Oncologist. 2015 Jan;20(1):37-44. PubMed PMID: 25492923.
 
Portnow J, Badie B, Chen M, Liu A, Blanchard S, Synold TW. The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. Clin Cancer Res. 2009 Nov 15;15(22):7092-8. PubMed PMID: 19861433.
 
Portnow J, Badie B, Markel S, Liu A, D'Apuzzo M, Frankel P, Jandial R, Synold  TW. A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas. Eur J Cancer. 2013 May;49(7):1634-40. PubMed PMID: 23380277.
 
Portnow J, Badie B, Liu X, Frankel P, Mi S, Chen M, Synold TW. A pilot microdialysis study in brain tumor patients to assess changes in intracerebral cytokine levels after craniotomy and in response to treatment with a targeted anti-cancer agent. J Neurooncol. 2014 May;118(1):169-77. PubMed PMID: 24634191.
 
Portnow J, Synold TW, Badie B, Tirughana R, Lacey SF, D'Apuzzo M, Metz MZ, Najbauer J, Bedell V, Vo T, Gutova M, Frankel P, Chen MY, Aboody KS. Neural stem cell-based anti-cancer gene therapy: a first-in-human study in recurrent high grade glioma patients. Clin Cancer Res. 2016 Dec 15 [Epub ahead of print]. PubMed PMID: 27979915.
 
Portnow J, Badie B, Chen M, Liu A, Blanchard S, Synold TW. The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. Clin Cancer Res. 2009 Nov 15;15(22):7092-8. PubMed PMID: 19861433.
 
Portnow J, Badie B, Markel S, Liu A, D'Apuzzo M, Frankel P, Jandial R, Synold  TW. A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas. Eur J Cancer. 2013 May;49(7):1634-40. PubMed PMID: 23380277.
 
Portnow J, Badie B, Liu X, Frankel P, Mi S, Chen M, Synold TW. A pilot microdialysis study in brain tumor patients to assess changes in intracerebral cytokine levels after craniotomy and in response to treatment with a targeted anti-cancer agent. J Neurooncol. 2014 May;118(1):169-77. PubMed PMID: 24634191.
 
Portnow J, Synold TW, Badie B, Tirughana R, Lacey SF, D'Apuzzo M, Metz MZ, Najbauer J, Bedell V, Vo T, Gutova M, Frankel P, Chen MY, Aboody KS. Neural stem cell-based anti-cancer gene therapy: a first-in-human study in recurrent high grade glioma patients. Clin Cancer Res. 2016 Dec 15 [Epub ahead of print]. PubMed PMID: 27979915.
 
In The News